Although great progress have been achieved in treating neovascularization (CNV) secondary to age-related macular degeneration (AMD) in recent years, some essential problem should be considered in gaining better therapeutic results for CNV patients. Firstly we need to know clearly whether the CNV is classic or occult? Secondly we need to understand whether the CNV lesion is actually polypoidal choroidal vasculopathy (PCV) or retinal angiomatous proliferation (RAP)? Thirdly we need to determine to choose photodynamic therapy (PDT) or anti-vascular endothelial growth factor (VEGF) therapy or combination therapy for a individual AMD patient.